Impaired cardiac function is of course the primary problem in heart failure, but it is also the stimulus to activation of several integrated neuroendocrine systems. Activation of these neuroendocrine systems at first seems to have important beneficial effects for the failing circulation-maintaining cardiac output, blood pressure, blood flow to essential organs, and the glomerular filtration rate. Prolonged or extreme neuroendocrine activation, however, may prove deleterious.
The advent of effective diuretics had a tremendous impact on the management of patients with heart failure. Then, in the absence of a cure for the primary problem, thoughts returned to agents that either increased the force of myocardial contraction (inotropic agents) or reduced the load on the failing heart (vasodilator agents). Both modes of treatment have proved effective in improving haemodynamic function in the short term. Neither therapeutic intervention has yet been established as having beneficial effects for long term treatment of heart failure.
A fourth group of agents was added to the treatment of heart failure in the 1980s. The The relation between cardiac output and venous pressure in heart failure was described at the Hammersmith Hospital in the 1940s, and Wood recognised that increased systemic vasoconstriction was one of the hallmarks of heart failure.'2 These ideas were brought together by Braunwald in the 1960s, who integrated the concepts of altered pre-load, after-load, and myocardial contractility and promoted the theoretical rationale for vasodilator therapy for heart failure.3
However, the concept of reducing vascular tone in the treatment of heart failure is much older. Osler (1892) used nitroglycerine4 and Savill (1936) suggested sympathectomy5 as a treatment for intractable heart failure. These ideas gained substance in the 1950s, with the use of ganglion blocking agents6 and nitrates.7
Since then, nitrates have achieved a lasting place in the management of pulmonary oedema. The use of phentolamine in the 1970s ushered in the "modern" era of vasodilator therapy.8 However, despite all the theoretical considerations, until the appearance of ACE inhibitors in the 1980s, vasodilator agents achieved no firm practical role in the management of chronic heart failure.
Neuroendocrine consequences of heart failure The circulation responds both to changes in volume and to changes in pressure. Those reflexes which depend on pressure receptors (that is, carotid, aortic arch, and renal) seem to work fairly normally in heart failure,910 with reduction in arterial wall tension activating the sympathetic nervous and renin-angiotensinaldosterone systems. Though such reflexes may be slightly blunted they work in a directionally normal sense.
In contrast, volume dependent reflexes (that is, of the atria and great veins) seem to be markedly blunted or directionally abnormal. The diuresis that can be elicited by atrial distention is reduced. Although atrial natriuretic peptide is increased" its renal effects are considerably reduced in heart failure. Plasma concentrations of arginine vasopressin, which would normally be suppressed during atrial distention, are increased.
Animal models of heart failure suggest that initial activation of the sympathetic nervous and renin-angiotensin systems results in fluid retention and vasoconstriction.'2 If the primary myocardial insult is not too severe, fluid retension causes blood volume expansion with a restoration of arterial pressure, and as this occurs activation of the neuroendocrine systems wanes. This is consistent with observations in patients developing heart failure after myocardial infarction.'3 However, if the cardiac insult is severe enough haemodynamic equilibrium cannot be achieved. This may manifest itself in several ways; cardiogenic shock will result from an excessive fall in stroke output or pulmonary oedema from an excessive rise in left atrial pressure. Most patients with chronic heart failure are already receiving diuretics which prevent the patient from attaining haemodynamic equilibrium; therefore activation of vasoconstrictor neuroendocrine systems is maintained. Diuretics, by reversing fluid retention, reveal the underlying activation of the reninangiotensin system. High plasma concentrations of renin, angiotensin II, noradrenaline, and atrial natriuretic peptide are also important and indicate a poor prognosis.415 High concentrations of catecholamine and angiotensin II6 may be directly cardiotoxic as well as adding to a downward spiral of increasing vascular resistance, neuroendocrine activation, and deteriorating haemodynamic function. However, it is not certain whether neuroendocrine activation itself makes a contribution to increasing mortality or is just a marker of severity. The demonstration that normal concentrations ofplasma renin with high sympathetic activity may be exchanged for the converse by diuretics'7 illustrates the absence of any simple relation between neuroendocrine activation and prognosis. 
Management of the patient with acute pulmonary oedema according to the classic principles of reduction of pre and after load is effective, but these same haemodynamic concepts may be less appropriate in the management of chronic heart failure. Changes in skeletal muscle related to deconditioning,26 intracellular deficits of potassium,27 or excesses of sodium27 may also be important therapeutic targets in chronic heart failure, when the underlying cardiac abnormality itself cannot be corrected.
Clearly there is a big difference between the regional distribution of the cardiac output "driven" by the heart and output "led" by reducing the vascular resistance.
Tolerance to vasodilator agents: role of neuroendocrine activation Tolerance to vasodilators may be caused by metabolic changes in the vascular wall, as in the case of nitrates, leading to a loss of effect on vascular smooth muscle. In many instances, however, neuroendocrine and metabolic (mal)adaptations may be even more important, or the sole cause.
Administration of the powerful vasodilators minoxidil and diazoxide to patients with heart failure results in immediate beneficial haemodynamic effects, but gross fluid retention rapidly supervenes.2' A similar phenomenon, milder in degree, probably occurs with other arteriolar dilators, due to a fall in arterial pressure, and hence renal perfusion pressure. Associated increases in the activities of the sympathetic nervous and renin-angiotensinaldosterone systems can further exacerbate renal sodium retention.283 Increasing the dose of diuretic to reverse fluid retention leads to greater neuroendocrine activation, which will further reverse the vasodilatation. Increases in angiotensin II and the fall in perfusion pressure can cause a paradoxical fall in renal blood flow,3' and create a vicious cycle of declining renal function and increasing diuretic requirements. Agents that reduce atrial pressure are likely to exacerbate fluid retention still further by reducing atrial natriuretic peptide-though patients with heart failure seem less responsive to atrial peptide, it is not entirely devoid of action.
The development of tolerance means that no true test of the therapeutic effects of chronic vasodilation in heart failure can be made with "conventional" vasodilators 37 Studies that suggest that ACE inhibitors exert their benefits by increasing effective oxygen delivery to the exercising limb, in contrast with "conventional" vasodilators, are flawed in their argument. 38 Association does not equal causation. Increased exercise performance would be expected to lead to a more pronounced reduction in vascular resistance in response to the accumulation of vasodilating waste products in exercising muscle, which in turn will lead to increased blood flow. Improvements in blood flow during chronic therapy probably owe more to changes in vessel wall composition and the capacity of the vessel valve to respond to vasodilator stimuli rather than to simple direct vasodilatation.
Neuroendocrine effects ACE inhibitors exert most of their effects by reducing angiotensin II. The inhibition of bradykinin stimulation and the effects on prostaglandins are ofuncertain clinical significance. The immediate response to an ACE inhibitor is a reduction in the plasma concentrations of angiotensin II, aldosterone, noradrenaline, and atrial natriuretic peptide.39" Adrenaline and arginine vasopressin show little change unless hypotension is profound.4" Longer term inhibition of ACE results in continued supression of angiotensin II, aldosterone, and noradrenaline plus a decline in arginine vasopressin.3536 Increases in renin and angiotensin II activity in response to diuretics, standing, and exercise are prevented.42 Suppression of aldosterone declines with time, a result of a rise in serum potassium concentration, which stimulates aldosterone secretion. This is a useful safeguard against severe hyperkalaemia during ACE inhibition. Plasma noradrenaline is suppressed in the supine position, but increases in response to standing, a normal reflex usually absent in patients with heart failure. 42 The potassium is retained in the depleted intracellular compartment45 but the serum potassium eventually rises as the pre-treatment total body potassium depletion is corrected. Potassium sparing diuretics, which may be needed in the early days or weeks of treatment, can, if continued, lead to dangerous hyperkalaemia. Spironolactone is most likely to give rise to problems for the reasons outlined above.
Prediction of effect Just as there is a poor relation between clinical state and neuroendocrine activation, so activation of these systems is a poor predictor of response to an ACE inhibitor.' A modest correlation has been noted between the initial haemodynamic effects and plasma renin, which is lost during long term follow up. The increase in plasma renin in response to the first dose ofan ACE inhibitor may be a guide to long term efficacy.47
Conclusion
Although direct acting vasodilators might be expected to improve symptoms and exercise performance in heart failure, they have proved disappointing. Once again theoretical considerations have failed to work out in clinical practice. There is compelling evidence that their use in chronic heart failure leads to further neuroendocrine activation and that it is this which limits their therapeutic efficacy. ACE inhibitors were introduced as a new class of vasodilator agent and once again medical serendipity seems to be operating. ACE 
